Celecoxib in Parkinson Disease as Adjuvant Therapy

Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07246278

Enrollment

Registered

2025-11-24

Start date

2025-11-20

Completion date

2026-11-28

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Interventions

DRUGLevodopa Carbidopa

Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

DRUGCelecoxib 200mg

Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years. * Both male and female will be included. * Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion criteria

* Breast feeding * Patients with significant liver and kidney function abnormalities. * Alcohol and / or drug abusers. * Patients with known allergy to the study medications * Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib). * Pregnant women and women with planned pregnancy. * Patients who are currently using other anti-inflammatory drugs.

Design outcomes

Primary

Measure	Time frame	Description
change in the Unified Parkinson's Disease Rating Scale	6 months	\- Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026